GHICL-Hopital St Vincent de Paul
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TURLURE, Pascal
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Recruiting
2
33
Europe
AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
10/26
10/27
TMF-Allo, NCT04935684: Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Recruiting
2
150
Europe
Fecal Microbiota Transplantation
University Hospital, Clermont-Ferrand, Ministry of Health, France, French Society of Hematology
Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia
10/26
12/27
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)

Recruiting
2
387
Europe
Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo
MaaT Pharma
Transplant Complication
10/26
02/27
HAPLO-EMPTY, NCT05126849: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

Recruiting
2
31
Europe
Allogenic transplantation
Assistance Publique - Hôpitaux de Paris
Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
01/27
01/27
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
FLUCLORIC, NCT05917405: Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Recruiting
2
302
Europe
Fludarabine, Busulfan, ATG, Clofarabine
Nantes University Hospital
Acute Myeloid Leukemia in Remission
09/28
09/28
GFM, NCT05226455: Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Recruiting
1/2
55
Europe
venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza
Groupe Francophone des Myelodysplasies, AbbVie
MDS, AML
09/25
03/26
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
12/26
12/26
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Recruiting
N/A
230
Europe
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult
12/24
03/25
NAViRe, NCT04690933: AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients

Recruiting
N/A
400
Europe
Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
University Hospital, Limoges
Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antivirals, Antiviral Drug Resistance
09/22
12/24
CARPENTIER, Benjamin
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
ESCORT-HU Extension, NCT04707235: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Active, not recruiting
N/A
2093
Europe, RoW
Hydroxycarbamide, Siklos, Hydroxyurea
Theravia, International Clinical Trials Association
Sickle Cell Disease
08/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TURLURE, Pascal
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Recruiting
2
33
Europe
AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
10/26
10/27
TMF-Allo, NCT04935684: Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Recruiting
2
150
Europe
Fecal Microbiota Transplantation
University Hospital, Clermont-Ferrand, Ministry of Health, France, French Society of Hematology
Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia
10/26
12/27
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)

Recruiting
2
387
Europe
Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo
MaaT Pharma
Transplant Complication
10/26
02/27
HAPLO-EMPTY, NCT05126849: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

Recruiting
2
31
Europe
Allogenic transplantation
Assistance Publique - Hôpitaux de Paris
Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
01/27
01/27
AGORA-1, NCT05199051 / 2021-001813-35: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML

Recruiting
2
50
Europe
Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata
Centre Antoine Lacassagne, Acute Leukemia French Association, Astellas Pharma Inc, Pfizer
AML
03/27
03/27
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Recruiting
2
210
Europe
Cytarabine and Idarubicin, CPX-315
Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association
Acute Myeloid Leukemia
10/27
10/27
FLUCLORIC, NCT05917405: Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Recruiting
2
302
Europe
Fludarabine, Busulfan, ATG, Clofarabine
Nantes University Hospital
Acute Myeloid Leukemia in Remission
09/28
09/28
GFM, NCT05226455: Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Recruiting
1/2
55
Europe
venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza
Groupe Francophone des Myelodysplasies, AbbVie
MDS, AML
09/25
03/26
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
12/26
12/26
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Recruiting
N/A
230
Europe
French Innovative Leukemia Organisation, Acute Leukemia French Association
AML, Adult
12/24
03/25
NAViRe, NCT04690933: AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients

Recruiting
N/A
400
Europe
Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
University Hospital, Limoges
Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Antivirals, Antiviral Drug Resistance
09/22
12/24
CARPENTIER, Benjamin
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting
N/A
2500
Europe
Acute Leukemia French Association
Acute Myeloid Leukemia (AML)
04/32
04/46
ESCORT-HU Extension, NCT04707235: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Active, not recruiting
N/A
2093
Europe, RoW
Hydroxycarbamide, Siklos, Hydroxyurea
Theravia, International Clinical Trials Association
Sickle Cell Disease
08/25
08/25

Download Options